SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

13 May 2025 Evaluate
The Sales for the quarter ended March 2025 of Rs. 14.67 million declined by -38.49% from Rs. 23.85 millions.The Net Loss for the quarter ended March 2025 is Rs. -150.70 millions as compared to Net Loss of Rs. -31.25 millions of corresponding quarter ended March 2024 Operating profit Margin for the quarter ended March 2025 further decreased to -137.23% as compared to -25.87% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 14.67 23.85 -38.49 66.56 116.93 -43.08 66.56 116.93 -43.08
Other Income 11.91 42.83 -72.19 107.26 211.30 -49.24 107.26 211.30 -49.24
PBIDT -137.23 -25.87 430.46 -412.11 -98.07 320.22 -412.11 -98.07 320.22
Interest 0.00 0.30 0.00 0.47 1.58 -70.25 0.47 1.58 -70.25
PBDT -137.23 -26.17 424.38 -412.58 -25.08 1545.06 -412.58 -25.08 1545.06
Depreciation 13.47 15.10 -10.79 58.22 65.02 -10.46 58.22 65.02 -10.46
PBT -150.70 -41.27 265.16 -470.80 -90.10 422.53 -470.80 -90.10 422.53
TAX 0.00 -10.02 0.00 0.00 -10.02 0.00 0.00 -10.02 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -150.70 -31.25 382.24 -470.80 -80.08 487.91 -470.80 -80.08 487.91
Equity 218.07 218.07 0.00 218.07 218.07 0.00 218.07 218.07 0.00
PBIDTM(%) -935.45 -108.47 762.40 -619.16 -83.87 638.23 -619.16 -83.87 638.23

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×